Cytokinetics has been granted a patent for pharmaceutical formulations of omecamtiv mecarbil, including specific ingredients and methods for preparation. The formulation includes omecamtiv mecarbil dihydrochloride hydrate, control release agent, pH modifying agent, filler, and lubricant. GlobalData’s report on Cytokinetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cytokinetics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cytokinetics, NSAID cancer drugs was a key innovation area identified from patents. Cytokinetics's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Formulation of omecamtiv mecarbil for pharmaceutical use

Source: United States Patent and Trademark Office (USPTO). Credit: Cytokinetics Inc

A recently granted patent (Publication Number: US11884630B2) discloses a pharmaceutical formulation containing omecamtiv mecarbil dihydrochloride hydrate, a controlled release agent, a pH modifying agent (maleic acid, fumaric acid, tartaric acid, glutamic acid, or a combination), a filler, and a lubricant. This formulation is intended for the treatment of diseases associated with systolic heart dysfunction. The patent specifies the use of specific ingredients in precise quantities to achieve the desired therapeutic effect.

Furthermore, the patent outlines variations in the pharmaceutical formulation, including different concentrations of omecamtiv mecarbil dihydrochloride hydrate, alternative control release agents, pH modifying agents, fillers, and lubricants. The formulations are designed to be administered in tablet form. The patent emphasizes the importance of these specific compositions in effectively treating systolic heart dysfunction. Overall, the patent provides detailed information on the formulation and method of using omecamtiv mecarbil dihydrochloride hydrate for therapeutic purposes, particularly in the context of heart-related conditions.

To know more about GlobalData’s detailed insights on Cytokinetics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies